Evidence-based clinical practice guidelines for the use of recombinant and plasma-derived FVIII and FIX products
Bywood, P, Newton, S, Mundy, L, Merlin, T, Saxon, B, Hiller, J
Record ID 32006001416
English
Authors' objectives:
The main objectives of this guideline document were to develop 1) national clinical practice guidelines for the use of recombinant factors VIII and IX for patients with Haemophilia A and B; 2) national clinical guidelines for the use of plasma-derived factors for patients with von Willebrand Disease; and 3) national tolerisation protocols for tasks 1) and 2) above.
Details
Project Status:
Completed
Year Published:
2006
URL for published report:
http://www.blood.gov.au/system/files/documents/fviii-fix-guidelines.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Clinical Protocols
- Practice Guidelines as Topic
- Time Factors
- Factor IX
- Factor VIII
- Hemophilia A
- Hemophilia B
- Hemorrhage
- Recombinant Proteins
Contact
Organisation Name:
Adelaide Health Technology Assessment
Contact Address:
School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
ahta@adelaide.edu.au
Contact Email:
ahta@adelaide.edu.au
Copyright:
Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.